Skip to main content

Scientific Industries Reports Financial Results for Second Quarter of Fiscal Year 2025

TORBAL DIVISION SALES UP 11%SECURED $10 MILLION IN STRATEGIC DIVESTURE OF GENIE PRODUCT LINEVIVID AND BIOPROCESSING NEW PRODUCT AI ROADMAP ON TARGET Investor Call to be held Wednesday, August 20th at 11:00 a.m. Eastern Time BOHEMIA, N.Y., Aug. 19, 2025 (GLOBE NEWSWIRE) — Scientific Industries, Inc. (OTCQB: SCND), a developer of digitally simplified bioprocessing products and vision-based pill counters, today reported financial results for the three and six month periods ended June 30, 2025. Business Highlights:Secured $10 million through sale of Genie Division subsequent to quarter-end Reported 11% increase in sales of its Torbal Division year-over-year VIVID sales up 16% year-over-year DOTS MPS Platform was proven in a customer study to dramatically improve productivity2025 Second Quarter Financial Overview:Net revenues...

Continue reading

ScanTech AI Strengthens Service Capabilities by Selecting Curie Technologies

ScanTech AI Strengthens Service Capabilities by Selecting Curie TechnologiesScanTech AI Strengthens Service Capabilities by Selecting Curie TechnologiesAtlanta, GA, Aug. 19, 2025 (GLOBE NEWSWIRE) — ScanTech AI Systems Inc. (the “Company” or “ScanTech AI”) (Nasdaq: STAI), a next-generation provider of AI-powered CT screening systems for aviation, customs, and critical infrastructure, today announced its service collaboration with Curie Technologies to integrate the Curie™ software platform into its SENTINEL™ CT (Computed Tomography) offering to enhance service delivery and customer success. This initiative underscores ScanTech AI’s commitment to delivering exceptional customer value and advancing digital service innovation across mission-critical markets. The Curie™ platform,...

Continue reading

Canadian Net REIT Announces 2025 Second-Quarter Results

REIT also announces monthly distributions for Q4 2025 MONTRÉAL, Aug. 19, 2025 (GLOBE NEWSWIRE) — Canadian Net Real Estate Investment Trust (“Canadian Net” or the “REIT”) (TSX-V: NET.UN) today reported its results for the quarter ended June 30th, 2025 (“Q2 2025”) and distributions for October, November and December 2025. “We are pleased with our second quarter results, highlighted by an 8% year-to-date increase in FFO per unit1,” said Kevin Henley, President and CEO. “This quarter reflects the full impact of our recently acquired properties, demonstrating the success of our disciplined growth strategy. Our ability to generate accretive results through our capital recycling program continues to strengthen the REIT and create value for our unitholders. Our focused portfolio of single-tenant, triple-net, and necessity-based properties...

Continue reading

Orion Announces EV Charger Installations in Two Locations for Massachusetts DOT; FY26 Growth Illustrated by $15.5M in Revenue from 5 Enterprise Customers Announced in the Last 3 Weeks

MANITOWOC, Wis., Aug. 19, 2025 (GLOBE NEWSWIRE) — Orion Energy Systems, Inc. (NASDAQ: OESX) (Orion Lighting), a provider of energy-efficient LED lighting, electric vehicle (EV) charging stations and maintenance services solutions, today announced that it is installing four High Power DC EV chargers and related infrastructure at two sites for the Massachusetts Department of Transportation as part of a contract valued at $2 million. Orion’s Voltrek division is installing four High Power DC EV chargers for MassDOT at the Barnstable and Plymouth service plazas. The Orion/Voltrek installations are part of MassDOT’s five-year plan to deploy EV chargers throughout the Commonwealth, with a particular focus on travel plazas along the Massachusetts Turnpike. MassDOT is also involved in increasing the availability of charging stations in...

Continue reading

Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

Quarter highlighted by the key acquisition of The Sleep Center of Nevada, which is generating revenue and seeing strong patient demand for Vivos’ differentiated array of highly effective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children ages 6 – 17), today reported financial results and operating highlights for the three and six months ended June 30, 2025. Kirk Huntsman, Vivos’ Chairman and Chief Executive...

Continue reading

LanzaTech Reports Second Quarter 2025 Financial Results

Continued Focus on Operational Execution and Strategic Transformation SKOKIE, Ill., Aug. 19, 2025 (GLOBE NEWSWIRE) — LanzaTech Global, Inc. (NASDAQ: LNZA) (“LanzaTech” or the “Company”), a carbon management solutions company, today reported its financial and operating results for the second quarter ended June 30, 2025. Second Quarter Highlights:Efficiency & Profitability Initiatives – In May and June 2025, LanzaTech announced certain transitions in its executive leadership team and reductions to its workforce in connection with its ongoing strategic measures to scale its global business with greater cost efficiency to support its transition from a research and development-centric company to a commercially focused enterprise. These changes reflect LanzaTech’s commitment to improving operating leverage and aligning its...

Continue reading

La-Z-Boy Incorporated Reports First Quarter Results; Led By Retail And Wholesale Delivered Sales Growth And Wholesale Margin Expansion; Retail Written Sales Up 5%

Fiscal 2026 First Quarter Highlights:Retail segment written sales increased 5% Retail segment delivered sales increased 2%Added two stores Announced 15-store acquisition, which is expected to close in late OctoberWholesale segment delivered sales increased 1%Successful transition of our Arizona distribution center to new West Coast centralized hubGAAP operating margin of 4.5% and adjusted(1) operating margin of 4.8% GAAP diluted EPS of $0.44 and adjusted(1) diluted EPS of $0.47 Generated $36 million in operating cash flow for the quarterMONROE, Mich., Aug. 19, 2025 (GLOBE NEWSWIRE) — La-Z-Boy Incorporated (NYSE: LZB), a global leader in the retail and manufacture of residential furniture, today reported first quarter results for the period ended July 26, 2025. For the quarter, sales totaled $492 million, down 1% against...

Continue reading

Fluent Announces Second Quarter 2025 Financial Results; Commerce Media Solutions Annual Revenue Run Rate Exceeds $80 Million

  • Q2 2025 revenue of $44.7 million; H1 2025 revenue of $99.9 million   • Q2 2025 Commerce Media Solutions revenue grew 121% to $16.1 million, representing 36% of consolidated revenue from $7.3 million or 12% of consolidated revenue in Q2 2024   • Commerce Media Solutions annual revenue run rate now exceeds $80 million, reflecting a 23% quarter-over-quarter increase and strong momentum in executing the Company’s strategic pivot to this higher growth market  • Expect adjusted EBITDA profitability in Q4 2025 as well as full-year double-digit revenue growth and full-year adjusted EBITDA profitability in 2026  • Subsequent to the quarter, raised $10.3 million from new investors and insiders     NEW YORK, Aug. 19, 2025 (GLOBE NEWSWIRE) — Fluent, Inc. (NASDAQ: FLNT), a commerce media solutions provider, today...

Continue reading

Carlyle Credit Income Fund Announces Third Quarter Financial Results and Declares Monthly Common and Preferred Dividends

NEW YORK, Aug. 19, 2025 (GLOBE NEWSWIRE) — Carlyle Credit Income Fund (“we,” “us,” “our,” “CCIF” or the “Fund”) (NYSE: CCIF) today announced its financial results for its third quarter ending June 30, 2025. The full detailed presentation of the Fund’s third quarter 2025 financial results can be viewed on the Fund’s website (carlylecreditincomefund.com/investor-dashboard). “We believe our third quarter performance reflects CCIF’s resilience in navigating a complex market environment,” said Nishil Mehta, CCIF’s Principal Executive Officer and President. “We continue to hold a diversified portfolio of CLO equity with ample time remaining in reinvestment period, providing third-party managers the flexibility to actively manage loan portfolios. During the quarter, we selectively deployed capital, completed two opportunistic resets,...

Continue reading

REPEAT — Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

Includes $36 million line of credit and potential $14 million private placementWARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) — Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, following the recent elimination of $94.9 million in balance sheet liabilities, has entered into a definitive agreement for up to $50 million in financing. This formalizes the binding term sheet previously announced May 10, 2024. Combined with this financing, Tevogen’s efficient and innovative business model is expected to support research and development, particularly focusing on TVGN 489 the company’s initial product from its ExacTcell™ technology platform, and...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.